| アブストラクト | PURPOSE: Some reports have described arterial hypertension (AH) in patients treated by serotonin reuptake inhibitor (SRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants. The mechanism remains discussed, some authors suggesting a role of SERT (SERotonin Transporter) inhibition whereas others discussing NET (NorEpinephrine Transporter) involvement. The present study used the pharmacoepidemiological-pharmacodynamic (PE-PD) method to investigate the role of these transporters in SRI- and SNRI-induced AH. METHODS: The study involved two successive approaches: first, a PE study (disproportionality analysis) investigating in VigiBase(R), the World Health Organization Individual Case safety Report (ICSR) database, the relationships between exposure to SRI AND SNRI, and reports of AH. The primary analysis compared patients receiving one SRI (or one SNRI) with non-users. Secondary analyses were performed according to the pharmacological classes. Results are expressed as reporting odds ratios (ROR) with 95% CI and information component (IC), an indicator for disproportionate Bayesian reporting. Second, we performed a PD study using linear regression analyses to explore the association between the AH signal and binding affinities for NET and SERT (expressed as their pKi ratio) of SRIs and SNRIs. RESULTS: A significant ROR value was found for each individual SRI (except fluvoxamine) and each individual SNRI. ROR values were also significant for SRIs and SNRIs in general with higher values for SNRIs than for SRIs. Similar trends were found using IC. A significant correlation was found between the signal of AH and the NET/SERT pKi ratio (y = 6.57x - 2.55, R(2) = 0.68, Pearson coefficient correlation = 0.82). CONCLUSION: The present study found a positive association between the NET/SERT pKi ratio and the occurrence of arterial hypertension with SRI and SNRI antidepressants. These results are important for the selection of antidepressants in hypertensive and/or at risk depressive patients as well as for future development of antidepressants devoid of hypertensive effect. |
|---|
| ジャーナル名 | European journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2020/6/3 |
|---|
| 投稿者 | Montastruc, Jean-Louis; Rousseau, Vanessa; de Canecaude, Claire; Roussin, Anne; Montastruc, Francois |
|---|
| 組織名 | Service de Pharmacologie Medicale et Clinique, Centre de Pharmacovigilance de;Pharmacoepidemiologie et d'Informations sur le Medicament, INSERM UMR 1027, CIC;1426, Faculte de Medecine, Centre Hospitalier Universitaire de Toulouse,;Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;Toulouse, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32483650/ |
|---|
